Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes

AIDS

Volumn 11, Issue 1, 1997, Pages 67-72

  Lafeuillade, Alain ^a,d   Tamalet, Catherine ^b   Poggi, Cécile ^a   Pellegrino, Pierre ^a   Tourres, Christian ^b   Izopet, Jacques ^c  

^a GENERAL HOSPITAL   (France)

^b La Conception   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d Hopital Chalucet Toulon   (France)

Author keywords

AIDS; Didanosine; Drug resistance; HIV; Lymph nodes; Viral load; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD CELL; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFECT; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPH NODE; LYMPH NODE BIOPSY; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROVIRUS; STATISTICAL ANALYSIS; T LYMPHOCYTE; VIREMIA;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; MALE; VIRAL LOAD; ZIDOVUDINE;

EID: 0031016049     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199701000-00010     Document Type: Article

References (30)

1. Delta Coordinating Committee: Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals, Lancet 1996, 348:283-291.
2. DeNoon DJ: ACTG 175: first-line AIDS therapy should be combination. AIDS Weekly Plus, 2 October 1995:3-4.
3. Collier AC, Coombs RW, Fischl MA, et al.: Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993, 119:786-793.
4. Kojima E, Shirasaka T, Anderson BD, et al.: Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J Infect Dis 1995, 171:1152-1158.
5. Shafer RW, Iversen AKN, Winters MA, et al.: Drug resistance and heterogenous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J Infect Dis 1995, 172:70-75.
6. Embretson J, Zupancic M, Ribas JL, et al.: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993, 362:359-362.
7. Pantaleo G, Graziosi C, Demarest JF, et al.: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362:355-358.
8. Tamalet C, Lafeuillade A, Yahi N, et al.: Comparison of viral burden and phenotype of HIV-1 isolates from lymph nodes and blood. AIDS 1994, 8:1083-1088.
9. Heath SL, Tew JG, Tew JG, Szakal AK, Burton GF: Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 1995, 377:740-744.
10. Cohen OJ, Pantaleo G, Holodniy M, et al.: Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci USA 1995, 82:6017-6021.
11. Kozal MJ, Shafer RW, Winters MA, et al.: HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. J Acquir Immune Defic Syndr 1994, 7:832-838.
12. Burgisser P, Spertini F, Suter C, Pagani JL, Meylan PRA: Monitoring the response to antiviral treatment in the lymph node of HIV-infected patients by serial fine needle aspiration. Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract 253].
13. Brettle RP, Gore SM, Bird AC, McNeil AJ: Clinical and epidemiological implications of the Centers for Disease Control/World Health Organization reclassification of AIDS cases. AIDS 1993, 7:531-539.
14. Rouzioux C, Puel J, Agut H, et al.: Comparative assessment of quantitative HIV viraemia assays. AIDS 1992, 6:373-377.
15. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S: Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994, 32:292-300.
16. Ju Lin H, Myers LE, Yen-Lieberman B, et al.: Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994, 170:553-562.
17. Izopet J, Tamalet C, Sandres K, et al.: Assessment of viral burden using PBMC culture and HIV-1 proviral DNA quantitation. Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract 561].
18. St Clair MH, Martin JL, Tudor-Williams G, et al.: Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991, 253:1557-1559.
19. Brun-Vézinet F, Ingrand D, Deforges L, et al.: HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. J Virol Methods 1992, 37:177-188.
20. Larder BA, Kellam P, Kemp SD: Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991, 5:137-144.
21. Larder B, Boucher CAB: Polymerase chain reaction detection of human immunodeficiency virus drug resistance mutations. In Diagnostic Molecular Microbiology. Principles and Applications. Edited by Persing DH, Smith TF, Tenover FC, White TJ. Washington, DC: American Society for Microbiology; 1993:527-533.
22. Yarchoan R, Lietzau JA, Nguyen BY, et al.: A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994, 169:9-17.
23. Cohen OJ, Pantaleo C, Holodniy M, et al.: Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. J Infect Dis 1996, 173:849-856.
24. Mole L, Holodniy M, Lalezari J, Banach M, Sension M, Scnittman S: The relationship between blood and lymph node viral load. Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract 259].
25. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
26. Lafeuillade, Poggi C, Profizi N, Tamalet C, Costes O: HIV-1 kinetics in lymph nodes compared to plasma. J Infect Dis 1996, 174:404-407.
27. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
28. Manouilov KK, White CA, Boudinot FD, Fedorov II, Chu CK: Lymphatic distribution of 3′-azido-3′-deoxythymidine and 3′-azido-2′,3′-dideoxyuridine in mice. Drug Metab Dispos 1995, 23:655-658.
29. Medina DJ, Tung PP, Lerner-Tung MB, Nelson CJ, Mellors JW, Strair RK: Sanctuary growth of human immunodeficiency virus in the presence of 3′-azido-3′-deoxythymidine. J Virol 1995, 69:1606-1611.
30. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996, 271:1582-1586.